 |
|
Study: Harmless virus kills some cancers
June 22, 2005HERSHEY, PA-Six days is all it takes for a common, non-disease-causing virus to kill cervical, breast, prostate and squamous cell cancer cells in laboratory cultures, according to Penn State College of Medicine researchers.
"Our results suggest that adeno-associated virus type 2 (AAV2), which infects the majority of the population but has no known ill effects, kills multiple types of cancer cells yet has no effect on healthy cells," said Craig Meyers, Ph.D., professor of microbiology and immunology, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center. "We believe that AAV2 recognizes that the cancer cells are abnormal and destroys them. This suggests that AAV2 has great potential to be developed as an anti-cancer agent."
The study was presented June 20, 2005, at the 24th annual meeting of the American Society for Virology held June 18-22 at Penn State, University Park campus.
Although the reason why remains unclear, population-based studies have shown that people who carry AAV2 tend not to develop human papillomavirus- (HPV-) associated cervical cancer. In general, AAV2 requires association with a helper virus in order to replicate. When it finds a helper virus, such as HPV, AAV2 disrupts the life cycle of the host and induces apoptosis, a type of cell death.
"Even without co-mingling with another virus, AAV2 seems to be able to infect and express itself in other types of cancer cells also disrupting their ability to survive and inducing cell death," Meyers said. "Although we suspect it is, more studies are needed to determine if the mechanism through which AAV2 destroys cancer cells is the same."
Scientists often refer to cancer cells as deregulated, meaning they are no longer acting or communicating like normal, healthy cells. It appears that AAV2 is able to recognize cells that have undergone deregulation, infect them, express its own genes, which disrupt the host cell's life cycle and kill it.
Scientists have suspected that AAV2 has cancer-suppressing properties. In previous studies, Meyers and his team found that one of the ways AAV2 suppresses cancer is by inhibiting the normal process of DNA duplication of human papillomavirus (HPV). HPV is known to lead to cervical cancer. A second way AAV2 suppresses cancer is linked to its ability to slow cell-cycle progression by decreasing cancer cell proliferation rates and causing growth arrest.
In this study, the team first used HPV infected epithelial cells and normal human epithelial cells, which are natural hosts for both AAV2 and HPV. In cultures infected with both AAV2 and HPV, the team found that after six days, all HPV infected cells had died. Meyers then used the same approach in four types of cancer - cervical, breast, prostate and squamous cell-all epithelial cell cancers. Epithelial cells are those that cover or line all of the internal and external parts of the body. No matter the type of epithelial cancer cells, when treated with AAV2, all cancer cells were dead in six days. Though previous have investigated the cancer-targeting potential of AAV2, none allowed the AAV2 to remain in culture long enough to see the effect that Meyers and his team observed.
"One of the most compelling findings is that AAV2 appears to have no pathologic effects on healthy cells," Meyers said. "So many cancer therapies are as poisonous to healthy cells as they are to cancer cells. A therapy that is able to distinguish between healthy and cancer cells could be less difficult to endure for those with cancer."
Though similar in design and effectiveness to some gene therapies, Meyers and his team did not modify the AAV2, but left it in its natural form. Therefore, it would not be classified as a gene therapy.
Future studies will investigate the precise mechanisms through which AAV2 causes cancer cell death, and how the virus might be enhanced to more aggressively target and kill cancers.
A provisional patent application for this work was recently submitted.
Penn State
Although the reason why remains unclear, population-based studies have shown that people who carry AAV2 tend not to develop human papillomavirus- (HPV-) associated cervical cancer. In general, AAV2 requires association with a helper virus in order to replicate. When it finds a helper virus, such as HPV, AAV2 disrupts the life cycle of the host and induces apoptosis, a type of cell death.
"Even without co-mingling with another virus, AAV2 seems to be able to infect and express itself in other types of cancer cells also disrupting their ability to survive and inducing cell death," Meyers said. "Although we suspect it is, more studies are needed to determine if the mechanism through which AAV2 destroys cancer cells is the same."
Scientists often refer to cancer cells as deregulated, meaning they are no longer acting or communicating like normal, healthy cells. It appears that AAV2 is able to recognize cells that have undergone deregulation, infect them, express its own genes, which disrupt the host cell's life cycle and kill it.
Scientists have suspected that AAV2 has cancer-suppressing properties. In previous studies, Meyers and his team found that one of the ways AAV2 suppresses cancer is by inhibiting the normal process of DNA duplication of human papillomavirus (HPV). HPV is known to lead to cervical cancer. A second way AAV2 suppresses cancer is linked to its ability to slow cell-cycle progression by decreasing cancer cell proliferation rates and causing growth arrest.
In this study, the team first used HPV infected epithelial cells and normal human epithelial cells, which are natural hosts for both AAV2 and HPV. In cultures infected with both AAV2 and HPV, the team found that after six days, all HPV infected cells had died. Meyers then used the same approach in four types of cancer - cervical, breast, prostate and squamous cell-all epithelial cell cancers. Epithelial cells are those that cover or line all of the internal and external parts of the body. No matter the type of epithelial cancer cells, when treated with AAV2, all cancer cells were dead in six days. Though previous have investigated the cancer-targeting potential of AAV2, none allowed the AAV2 to remain in culture long enough to see the effect that Meyers and his team observed.
"One of the most compelling findings is that AAV2 appears to have no pathologic effects on healthy cells," Meyers said. "So many cancer therapies are as poisonous to healthy cells as they are to cancer cells. A therapy that is able to distinguish between healthy and cancer cells could be less difficult to endure for those with cancer."
Though similar in design and effectiveness to some gene therapies, Meyers and his team did not modify the AAV2, but left it in its natural form. Therefore, it would not be classified as a gene therapy.
Future studies will investigate the precise mechanisms through which AAV2 causes cancer cell death, and how the virus might be enhanced to more aggressively target and kill cancers.
A provisional patent application for this work was recently submitted.
Penn State
Cancer Cells Current Events and Cancer Cells News RSSResearchers Discover New Enzyme in Cancer Growth
While studying the mechanics of blood clots, researchers at the University of Oklahoma Health Sciences Center discovered a new enzyme that not only affects the blood, but seems to play a primary role in how cancer tumors expand and spread throughout the body.
St. Jude identifies genomic causes of a certain type of leukemia relapse
Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to designing treatments for ALL relapse in children and, ultimately, in adults.
Prostate cancer spurs new nerves
Prostate cancer - and perhaps other cancers - promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.
Tiny protein provokes healthy bonding between cells
In human relationships, a certain "spark" often governs whether we prefer one person to another, and critical first impressions can occur within seconds. A team lead by Johns Hopkins researchers has found that cell-to-cell "friendships" operate in much the same way and that dysfunctional bonding is linked to the spread of cancer.
Studies show novel device may enhance chemotherapy treatment in brain tumors
NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.
Med school discovery could lead to better cancer diagnosis, drugs
A Florida State University College of Medicine research team led by Yanchang Wang has discovered an important new layer of regulation in the cell division cycle, which could lead to a greater understanding of the way cancer begins.
New platinum-phosphate compounds kill ovarian cancer cells
A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Nontoxic nanoparticle can deliver and track drugs
A nontoxic nanoparticle developed by Penn State researchers is proving to be an all-around effective delivery system for both therapeutic drugs and the fluorescent dyes that can track their delivery.
2 new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
More Cancer Cells Current Events and Cancer Cells News Articles
 | One Renegade Cell: The Quest For The Origin Of Cancer (Science Masters) by Robert A. Weinberg One of the leading cancer researchers in the world, Robert A. Weinberg is perfectly suited to describe the search for cancer's origins from the early days of this century to the present. Presuming little knowledge of biology, he tells how a cancer-causing virus was first discovered in 1909, how the correlation was made between chemical carcinogens and cancer, and how oncogenes (the genes that can... |
 | Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings) Cancer stem cells werehave originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug- resistance mechanisms. Current treatments might largely spare cancer stem cells, thus leading to tumor recurrence and metastasis. The recent identification of growth... |
 | Cancer Stem Cells: Identification and Targets Because the concept and discoveries of cancer stem cells are relatively new, scientists and researchers need an introduction to this dynamic area. Cancer Stem Cells presents a consolidated account of the research done to date and recent progresses in the studies of cancer stem cells. Such a presentation facilitates a better understanding of and draws attention to stem cell and cancer biology -... |
 | The Biology of Cancer HB by Robert A. Weinberg The Biology of Cancer is a comprehensive, authoritative, up-to-date textbook written by a major researcher in the field. It clearly presents the principles of cancer biology in an organized and accessible fashion. The information unfolds through the presentation of key experiments which give readers a sense of discovery, and provides insights into the conceptual foundation underlying cancer... |
 | Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease: A Biopsychosocial Approach Over recent decades, tremendous advances in the prevention, medical treatment, and quality of life issues in children and adolescents surviving cancer have spawned a host of research on pediatric psychosocial oncology. This important volume fulfills the clear need for an up-to-date, comprehensive handbook for practitioners that delineates the most recent research in the field--the first of its... |
 | Introduction to the Cellular and Molecular Biology of Cancer This new edition o Introduction and Molecular Biology of Cancer provides a concise yet comprehensive overview of cancer biology, covering the current status of both research and treatment. For the student or new researcher the breadth of cancer research can appear daunting, yet a broad understanding is essential for translation of laboratory findings into the clinic. Within the broad scope of... |
 | Cancer Cell Culture: Methods and Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) Expert researchers describe in detail their most productive and up-to-date methods for growing cancer cells in the laboratory. There are methods to characterize and authenticate cell lines, to isolate and develop specific types of cancer cells, and to develop new cell line models. Functional assays are provided to evaluate clonogenicity, cell proliferation, apoptosis, adhesion, migration,... |
 | Cancer Cell Metabolism and Cancer Treatment by Aurel Lupulescu Cancer cell metabolism is a vital phenomenon of cancer biology that has been virtually ignored in the past. However, recently it has been discovered that cancer cell metabolism plays a significant role in the metabolic regulation of gene expression. Specifically, research has shown that cancer cell metabolism affects the metabolic activation of cancer drugs, the expression of metabolic... |
 | Regulatory T Cells and Clinical Application The immune system reacts vigorously to foreign invaders such as viruses, bacteria, protozoa, and parasites, and yet shows unresponsiveness to our own proteins. Immune tolerance to self-proteins is paramount to prevent the development of autoimmune disease. In the past decade, several types of T lymphocytes in the immune system have been discovered to function as regulatory cells to suppress... |
| Cancer Cells by E.V. Cowdry |
| © 2008 BrightSurf.com |